Company
Headquarters: London, United Kingdom
Employees: 6
CEO: Mr. Robert Rauker
| Company | Market Cap (USD) |
|---|---|
| Abbott | $216.15 B |
| Boston Scientific Corporation | $140.40 B |
| Stryker | $133.15 B |
| Medtronic | $123.20 B |
| Edwards Lifesciences Corporation | $50.10 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Belluscura plc develops and commercialize oxygen related medical device products. The company offers X-PLO2R, a modular portable oxygen concentrator. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
| Last Financial Reports Date | June 30, 2023 |
| Revenue TTM | £958,438 |
| EBITDA | £-6,233,422 |
| Gross Profit TTM | £68,105 |
| Profit Margin | 4.87% |
| Operating Margin | -1090.44% |
| Quarterly Revenue Growth | -34.80% |
Belluscura plc has the following listings and related stock indices.
Stock: LSE: BELL wb_incandescent
Stock: FSX: 9VQ wb_incandescent